In clinical settings, afatinib has demonstrated efficacy as a viable first-line intervention for NSCLC patients harboring EGFR mutations, leading to improved progression-free survival compared to standard chemotherapy [70]. Here, EGFR is linked to non-small cell lung carcinoma.